SANOFI3,109.80

Sanofi India Limited

· Pharma & Health
₹ CrorePeersSENORESINNOVACAPPGHLMOREPENLABIOLCPSANOFICONRFDCORCHPHARMAMcap ₹7,153 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/12/2022
FY24
31/12/2023
FY25
31/12/2024
Inventory Days (DIO)270.91429.28514.17
Receivable Days (DSO)17.0116.8641.70
Payable Days (DPO)188.51417.98
Cash Conversion Cycle (days)257.63137.89
Working Capital Turnover3.194.783.69
Asset Turnover1.341.661.25
Cash Conversion (CFO/Net Income)0.381.12
CFO/EBITDA0.290.94
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.